carglumic acid has been researched along with Metabolic Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, P; Gu, X; Huang, HY; Liang, XF; Wu, XF; Xue, M | 1 |
| Burton, B; Caldovic, L; Daikhin, Y; Horyn, O; Korson, M; Nissim, I; Tuchman, M; Yudkoff, M | 1 |
1 trial(s) available for carglumic acid and Metabolic Diseases
| Article | Year |
|---|---|
N-carbamylglutamate markedly enhances ureagenesis in N-acetylglutamate deficiency and propionic acidemia as measured by isotopic incorporation and blood biomarkers.
Topics: Acetyl Coenzyme A; Adult; Amino Acids; Ammonia; Biomarkers; Carbon Dioxide; Carbon Isotopes; Child; Feasibility Studies; Female; Glutamates; Humans; Male; Metabolic Diseases; Middle Aged; Propionates; Urea | 2008 |
1 other study(ies) available for carglumic acid and Metabolic Diseases
| Article | Year |
|---|---|
Dietary N-Carbamylglutamate (NCG) alleviates liver metabolic disease and hepatocyte apoptosis by suppressing ERK1/2-mTOR-S6K1 signal pathway via promoting endogenous arginine synthesis in Japanese seabass (Lateolabrax japonicus).
Topics: Animal Feed; Animals; Apoptosis; Arginine; Bass; Diet; Dietary Supplements; Dose-Response Relationship, Drug; Fish Diseases; Fish Proteins; Glutamates; Hepatocytes; Liver Diseases; Metabolic Diseases; Nutrients; Random Allocation; Signal Transduction | 2019 |